Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study

Movement Disorders

Volumn 31, Issue 5, 2016, Pages 644-652

  Litvan, Irene ^a,b,d   Lees, Peter S J ^c   Cunningham, Christopher R ^a   Rai, Shesh N ^d   Cambon, Alexander C ^d   Standaert, David G ^e,t   Marras, Connie ^f   Juncos, Jorge ^g,n   Riley, David ^h,o   Reich, Stephen ^i,q   Hall, Deborah ^j,k,r,s   Kluger, Benzi ^k,s   Bordelon, Yvette ^l,p   Shprecher, David R ^m   Shepherd, Cassandra ^d   Johnson, Arik ^p   Holmes, Katherine ^q   McMurray, Rebecca ^t   Shprecher, David ^u   Wall, Paola ^u   Rothberg, Brandon ^f   Hennessy, Carol ^s   more..

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e The University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h InMotion   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j RUSH MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q UNIVERSITY OF MARYLAND   (United States)

^r RUSH UNIVERSITY   (United States)

^s UNIVERSITY OF COLORADO   (United States)

^t UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^u UNIVERSITY OF UTAH   (United States)

more..

Author keywords

Case control study; Epidemiology; Parkinsonism; Progressive supranuclear palsy; Risk factors

Indexed keywords

WELL WATER;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RISK ASSESSMENT; RISK FACTOR; SMOKING; WATER SUPPLY; CLINICAL TRIAL; MIDDLE AGED; NORTH AMERICA; OCCUPATIONAL DISEASE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; RISK FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE; WATER WELLS;

EID: 84958817853     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26512     Document Type: Article

References (36)

1. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013;70(7):859-866.
2. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354(9192):1771-1775.
3. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1-9.
4. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49(5):1284-1288.
5. Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 2003;18(Suppl 6):S43-S50.
6. Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010;133(Pt 6):1578-1590.
7. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology 1988;38(10):1546-1552.
8. Golbe LI, Rubin RS, Cody RP, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996;47(1):148-154.
9. Vidal JS, Vidailhet M, Derkinderen P, de Gaillarbois TD, Tzourio C, Alperovitch A. Risk factors for progressive supranuclear palsy: a case-control study in France. J Neurol Neurosurg Psychiatry 2009;80(11):1271-1274.
10. Gerstenecker A, Mast B, Duff K, Ferman TJ, Litvan I. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol 2013;28(2):104-113.
11. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry 2003;18(4):318-324.
12. Rocca WA, Maraganore DM, McDonnell SK, Schaid DJ. Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol 1998;51(6):517-523.
13. Stewart PA, Stewart WF, Heineman EF, Dosemeci M, Linet M, Inskip PD. A novel approach to data collection in a case-control study of cancer and occupational exposures. Int J Epidemiol 1996;25(4):744-752.
14. Breslow N. Design and Analysis of Case-Control Studies. Ann Rev Public Health 1982;3:29-54.
15. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: Wiley & Sons; 2000.
16. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian J Stat 1979;6:65-70.
17. SAS I, Inc.. SAS software 9.2 of the SAS System for Windows. ed. Cary, NC. 2002-2008.
18. Gauderman W, Morrison J, 2007:. QUANTO 1.2: a computer program for power and sample size calculations for genetic-epidemiology studies. Available at: http://hydra.usc.edu/gxe.; 2007.
19. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001;24(6):347-353.
20. Odetti P, Garibaldi S, Norese R, et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000;59(5):393-397.
21. Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JP, Beal MF. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 1999;73(2):881-884.
22. Lorenzl S, Albers DS, Chirichigno JW, Augood SJ, Beal MF. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. J Neurol Sci 2004;218(1-2):39-45.
23. Albers DS, Swerdlow RH, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 2001;168(1):196-198.
24. Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem 1994;62(4):1631-1634.
25. Champy P, Hoglinger GU, Feger J, et al. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004;88(1):63-69.
26. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000;21(4):435-440.
27. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011;119(6):866-872.
28. Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009;66(4):494-504.
29. James KA, Hall DA. Groundwater pesticide levels and the association with Parkinson disease. Int J Toxicol 2015;34(3):266-273.
30. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect 2009;117(12):1912-1918.
31. Caparros-Lefebvre D, Golbe LI, Deramecourt V, et al. A geographical cluster of progressive supranuclear palsy in northern France. Neurology 2015;85(15):1293-1300.
32. Vanacore N, Bonifati V, Fabbrini G, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000;54(1):114-119.
33. Tzourio C, Rocca WA, Breteler MM, et al. Smoking and Parkinson's disease. Neurology 1997;49:1267-1272.
34. Stewart PA, Stewart WF. Occupational case-control studies: II. Recommendations for exposure assessment. Am J Ind Med 1994;26(3):313-326.
35. Hall DA, Stebbins GT, Litvan I, et al. Clinimetric analysis of the motor section of the Progressive Supranuclear Palsy Rating Scale: reliability and factor analysis. Mov Disord 2015; in press.
36. Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53(6):1292-1299.